WuXi AppTec Co Ltd
SSE:603259
| US |
|
Fubotv Inc
NYSE:FUBO
|
Media
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
| US |
|
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
| CN |
|
NIO Inc
NYSE:NIO
|
Automobiles
|
| US |
|
Fluor Corp
NYSE:FLR
|
Construction
|
| US |
|
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
| US |
|
TopBuild Corp
NYSE:BLD
|
Consumer products
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
Health Care
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
| US |
|
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
| US |
|
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
| US |
|
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
| US |
|
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
| US |
|
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
36.87
84.68
|
| Price Target |
|
We'll email you a reminder when the closing price reaches CNY.
Choose the stock you wish to monitor with a price alert.
|
|
Fubotv Inc
NYSE:FUBO
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
C
|
C3.ai Inc
NYSE:AI
|
US |
|
|
Uber Technologies Inc
NYSE:UBER
|
US |
|
|
NIO Inc
NYSE:NIO
|
CN |
|
|
Fluor Corp
NYSE:FLR
|
US |
|
|
Jacobs Engineering Group Inc
NYSE:J
|
US |
|
|
TopBuild Corp
NYSE:BLD
|
US |
|
|
Abbott Laboratories
NYSE:ABT
|
US |
|
|
Chevron Corp
NYSE:CVX
|
US |
|
|
Occidental Petroleum Corp
NYSE:OXY
|
US |
|
|
Matrix Service Co
NASDAQ:MTRX
|
US |
|
|
Automatic Data Processing Inc
NASDAQ:ADP
|
US |
|
|
Qualcomm Inc
NASDAQ:QCOM
|
US |
|
|
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
WuXi AppTec Co Ltd
WuXi AppTec Co Ltd
Net Income (Common)
WuXi AppTec Co Ltd
Net Income (Common) Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Net Income (Common) | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
WuXi AppTec Co Ltd
SSE:603259
|
Net Income (Common)
¥8.5B
|
CAGR 3-Years
30%
|
CAGR 5-Years
33%
|
CAGR 10-Years
N/A
|
|
|
Pharmaron Beijing Co Ltd
SZSE:300759
|
Net Income (Common)
¥1.9B
|
CAGR 3-Years
15%
|
CAGR 5-Years
39%
|
CAGR 10-Years
N/A
|
|
|
WuXi Biologics (Cayman) Inc
HKEX:2269
|
Net Income (Common)
¥2.6B
|
CAGR 3-Years
-2%
|
CAGR 5-Years
26%
|
CAGR 10-Years
N/A
|
|
|
Hangzhou Tigermed Consulting Co Ltd
SZSE:300347
|
Net Income (Common)
¥958.7m
|
CAGR 3-Years
-24%
|
CAGR 5-Years
7%
|
CAGR 10-Years
24%
|
|
|
M
|
MGI Tech Co Ltd
SSE:688114
|
Net Income (Common)
-¥607.5m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
W
|
WuXi XDC Cayman Inc
HKEX:2268
|
Net Income (Common)
¥283.5m
|
CAGR 3-Years
121%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
WuXi AppTec Co Ltd
Glance View
WuXi AppTec Co., Ltd. is a prominent global healthcare platform that plays a pivotal role in empowering the pharmaceutical, biotechnology, and medical device industries. Founded in 2000 and headquartered in Shanghai, WuXi has cultivated a reputation for excellence through its extensive suite of services, which span the entire drug development lifecycle. From drug discovery to manufacturing, the company leverages cutting-edge technologies and a rich network of expertise to facilitate the development of innovative therapeutics. This comprehensive capability enables WuXi to serve as a trusted partner for clients, helping to streamline the complex path from concept to commercialization. With a focus on innovation and quality, WuXi AppTec has distinguished itself in the competitive landscape of contract research organizations (CROs) and contract manufacturing organizations (CMOs). The company's robust growth trajectory is underpinned by strategic investments in technology and infrastructure, as well as a commitment to expanding its global footprint. WuXi's expansive service offerings not only enhance operational efficiency for its partners but also align with the increasing demand for faster and more cost-effective drug development solutions. For investors, WuXi signifies an opportunity to engage with a market leader poised to capitalize on the burgeoning biopharmaceutical sector, driven by rising global healthcare needs and transformative advancements in science and technology.
See Also
What is WuXi AppTec Co Ltd's Net Income (Common)?
Net Income (Common)
8.5B
CNY
Based on the financial report for Jun 30, 2024, WuXi AppTec Co Ltd's Net Income (Common) amounts to 8.5B CNY.
What is WuXi AppTec Co Ltd's Net Income (Common) growth rate?
Net Income (Common) CAGR 5Y
33%
Over the last year, the Net Income (Common) growth was -10%. The average annual Net Income (Common) growth rates for WuXi AppTec Co Ltd have been 30% over the past three years , 33% over the past five years .
You don't have any saved screeners yet
